Literature DB >> 27623818

Outpatient antipsychotic drug use in children and adolescents in Germany between 2004 and 2011.

Carsten Schröder1, Michael Dörks2, Bianca Kollhorst3, Tilo Blenk1, Ralf W Dittmann4, Edeltraut Garbe1, Oliver Riedel5.   

Abstract

Studies from different countries showed increasing use of antipsychotics in pediatric patients. However, these studies were methodologically limited and could not assess underlying diagnoses and off-label use sufficiently. This is the first study to examine antipsychotic prescriptions in a representative sample of minors over a long period, looking at changes regarding substances and drug classes, underlying diagnoses, and the rate of off-label use. Claims data of about two million pediatric subjects were used to calculate annual prevalences and incidence rates of antipsychotic prescriptions for the years 2004-2011. Analyses were stratified by sex, age, and drug type. Numbers of prescriptions, frequencies of diseases/disorders, the prescribing physicians' specialties, and the share of off-label prescriptions were examined. During the study period, the prevalence of antipsychotic prescriptions ranged between 2.0 and 2.6 per 1000 minors. Antipsychotic prescriptions in children younger than 6 years decreased from 2.42 per 1000 subjects in 2004 to 0.48 in 2011. Among antipsychotic users, 47.0 % had only one prescription and hyperkinetic disorder was, by far, the most frequent diagnosis. The annual share of off-label prescriptions varied between 61.0 and 69.5 %. Antipsychotics were mainly prescribed to manage aggressive and impulsive behaviors in hyperkinetic disorder patients. This explains the high share of off-label prescriptions but raises concerns, since efficacy and safety of antipsychotics in this indication have not been sufficiently investigated. The decreasing antipsychotic use in younger children and the high proportion of antipsychotic users with one-time prescriptions are striking and should be further investigated in the future.

Entities:  

Keywords:  Adolescents; Antipsychotics; Children; Epidemiology; Neuroleptics; Off-label use

Mesh:

Substances:

Year:  2016        PMID: 27623818     DOI: 10.1007/s00787-016-0905-7

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  28 in total

1.  Antipsychotic prescribing in youths: a French community-based study from 2006 to 2013.

Authors:  Hélène Verdoux; Elodie Pambrun; Sébastien Cortaredona; Marie Tournier; Pierre Verger
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-01-07       Impact factor: 4.785

2.  The pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005-2009.

Authors:  Tamara Pringsheim; Darren Lam; Scott B Patten
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-12-02       Impact factor: 2.576

3.  Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study.

Authors:  S Turner; A J Nunn; K Fielding; I Choonara
Journal:  Acta Paediatr       Date:  1999-09       Impact factor: 2.299

4.  Use of antipsychotic drugs among Dutch youths between 1997 and 2005.

Authors:  Luuk J Kalverdijk; Hilde Tobi; Paul B van den Berg; Janelle Buiskool; Leonie Wagenaar; Ruud B Minderaa; Lolkje T W de Jong-van den Berg
Journal:  Psychiatr Serv       Date:  2008-05       Impact factor: 3.084

Review 5.  Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability.

Authors:  David Linton; Alasdair M Barr; William G Honer; Ric M Procyshyn
Journal:  Curr Psychiatry Rep       Date:  2013-05       Impact factor: 5.285

6.  National trends in the office-based treatment of children, adolescents, and adults with antipsychotics.

Authors:  Mark Olfson; Carlos Blanco; Shang-Min Liu; Shuai Wang; Christoph U Correll
Journal:  Arch Gen Psychiatry       Date:  2012-12

7.  Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany.

Authors:  Christina Lindemann; Ingo Langner; Angela A Kraut; Tobias Banaschewski; Tanja Schad-Hansjosten; Ulrike Petermann; Franz Petermann; Ina Schreyer-Mehlhop; Edeltraut Garbe; Rafael T Mikolajczyk
Journal:  J Child Adolesc Psychopharmacol       Date:  2012-08-02       Impact factor: 2.576

Review 8.  Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns.

Authors:  Benedetto Vitiello; Christoph Correll; Barbara van Zwieten-Boot; Alessandro Zuddas; Mara Parellada; Celso Arango
Journal:  Eur Neuropsychopharmacol       Date:  2009-05-24       Impact factor: 4.600

9.  Psychotropic drug use among Icelandic children: a nationwide population-based study.

Authors:  Helga Zoëga; Gísli Baldursson; Birgir Hrafnkelsson; Anna Birna Almarsdóttir; Unnur Valdimarsdóttir; Matthías Halldórsson
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-12       Impact factor: 2.576

10.  Psychotropic medication in children and adolescents in Germany: prevalence, indications, and psychopathological patterns.

Authors:  M Koelch; A Prestel; H Singer; F Keller; J M Fegert; R Schlack; H Hoelling; H Knopf
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-12       Impact factor: 2.576

View more
  9 in total

1.  Adolescent fluoxetine history impairs spatial memory in adult male, but not female, C57BL/6 mice.

Authors:  Francisco J Flores-Ramirez; Lyonna F Parise; Jason B Alipio; Israel Garcia-Carachure; Samuel A Castillo; Minerva Rodriguez; Anapaula Themman; Omar Lira; Joshua Preciado-Piña; Sergio D Iñiguez
Journal:  J Affect Disord       Date:  2019-02-19       Impact factor: 4.839

2.  Drug information center: challenges of the research process to answer enquiries in hospital pharmaceutical practices.

Authors:  Damiana da Rocha Vianna Flôres; Alexandre Augusto de Toni Sartori; Julia Borges Antunes; Alessandra Nunes Pinto; Julia Pletsch; Tatiane da Silva Dal Pizzol
Journal:  Eur J Hosp Pharm       Date:  2018-03-22

3.  First do no harm: use off-label antipsychotic medication in children and adolescents with great caution.

Authors:  Pieter J Hoekstra; Andrea Dietrich
Journal:  Eur Child Adolesc Psychiatry       Date:  2022-01       Impact factor: 4.785

4.  Antipsychotic Polypharmacy among Children and Young Adults in Office-Based or Hospital Outpatient Department Settings.

Authors:  Minji Sohn; Meghan Burgess; Mohamed Bazzi
Journal:  Pharmacy (Basel)       Date:  2017-11-23

5.  Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil.

Authors:  Izabela Fulone; Marcus Tolentino Silva; Luciane Cruz Lopes
Journal:  BMC Psychiatry       Date:  2021-06-29       Impact factor: 3.630

6.  'Use of antipsychotics in children and adolescents: a picture from the ARITMO population-based European cohort study'.

Authors:  Florentia Kaguelidou; Jakob Holstiege; Tania Schink; Irene Bezemer; Elisabetta Poluzzi; Giampiero Mazzaglia; Lars Pedersen; Miriam Sturkenboom; Gianluca Trifirò
Journal:  Epidemiol Psychiatr Sci       Date:  2020-04-20       Impact factor: 6.892

7.  New Users of Antipsychotics Among Children and Adolescents in 2008-2017: A Nationwide Register Study.

Authors:  Eveliina Varimo; Leena K Saastamoinen; Hanna Rättö; Hannu Mogk; Eeva T Aronen
Journal:  Front Psychiatry       Date:  2020-04-24       Impact factor: 4.157

8.  Pipamperone Population Pharmacokinetics Related to Effectiveness and Side Effects in Children and Adolescents.

Authors:  Sanne M Kloosterboer; Karin M Egberts; Brenda C M de Winter; Teun van Gelder; Manfred Gerlach; Manon H J Hillegers; Gwen C Dieleman; Soma Bahmany; Catrien G Reichart; Emma van Daalen; Mirjam E J Kouijzer; Bram Dierckx; Birgit C P Koch
Journal:  Clin Pharmacokinet       Date:  2020-11       Impact factor: 6.447

9.  Drug-naïve first-episode schizophrenia spectrum disorders: Pharmacological treatment practices in inpatient units in Hunan Province, China.

Authors:  Mengran Zhu; Maria Ferrara; Wenjian Tan; Xingbo Shang; Sumaiyah Syed; Li Zhang; Qilin Qin; Xinran Hu; Robert Rohrbaugh; Vinod H Srihari; Zhening Liu
Journal:  Early Interv Psychiatry       Date:  2020-09-14       Impact factor: 2.732

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.